Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Date: July 30, 2013
Pages: 56
US$ 3,495.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022
Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022


Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.
Roche/Genentech’s Tarceva is an EGFR TKI delivered as a daily oral tablet. It is approved by the FDA for use as a maintenance monotherapy and in second-line treatment after failure of at least one prior chemotherapy regimen for all patients, regardless of EGFR mutation status. In May 2013, the US FDA approved Tarceva’s label extension into the first-line therapy of EGFR-mutant patients, along with an EGFR companion diagnostic developed by Roche Diagnostics.

  • Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Tarceva including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Tarceva for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Tarceva performance
  • Obtain sales forecast for Tarceva from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)

1.1 List of Tables


2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports


3.1 Etiology and Pathophysiology
  3.1.1 Etiology
  3.1.2 Pathophysiology and Histology
  3.1.3 NSCLC Biomarkers
  3.1.4 Quality of Life
3.2 Symptoms


4.1 Treatment Overview
  4.1.1 Diagnosis
  4.1.2 Clinical Staging
  4.1.3 Screening and Early Detection
  4.1.4 Localized Procedures and Therapies
  4.1.5 Systemic Chemotherapy
  4.1.6 Targeted Therapy


5.1 Overview
5.2 Strategic Competitor Assessment


6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast


7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
  7.4.1 Number of NSCLC Patients Currently Seeking Treatment
  7.4.2 Percent Drug-treated Patients
  7.4.3 General Pricing Assumptions
  7.4.4 Individual Drug Assumptions
  7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in This Study
7.6 Survey of Prescribing Physicians
7.7 About the Authors
  7.7.1 Author
  7.7.2 Epidemiologist
  7.7.3 Global Head of Healthcare
7.8 About GlobalData
7.9 Disclaimer


Table 1: Symptoms of Disease NSCLC
Table 2: Treatment Guidelines for NSCLC
Table 3: Stage Definitions for NSCLC
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC
Table 5: Leading Treatments for NSCLC
Table 6: Product Profile – Tarceva (erlotinib hydrochloride)
Table 7: Tarceva SWOT Analysis, 2013
Table 8: Global Sales Forecasts ($m) for Tarceva, 2012-2022
Table 9: Five Year Prevalence
Table 10: Physicians Surveyed by Country
Skip to top

Ask Your Question

Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: